Lei Dong

Doctor of Medicine, Professor of the School of Life Sciences at Beijing Institute of Technology, Doctoral Supervisor

Engaged in research on the molecular mechanisms of the occurrence and development of Juvenile Myelomonocytic Leukemia (JMML) and the development of related drugs. The main research focuses on the pathogenic mechanisms of blood tumors caused by gene mutations, as well as the development and treatment of drugs targeting tumor-specific proteins. The research areas involve the pathogenesis and development mechanisms of leukemia and solid tumors, the structure and activation of phosphatases, and their functional regulation, etc.

2008.9-2012.7: PhD, University of Arkansas, USA
2005.9-2008.7: Master, Anhui Medical University, Clinical Medicine
2000.9-2005.7: Bachelor, Anhui Medical University, Clinical Medicine

2018.05-present: School of Life Sciences, Beijing Institute of Technology, Professor
2018: Selected as the first batch of "Special Young Scholars" of Beijing Institute of Technology
2012-2018: Postdoctoral and research assistant at Western Reserve University (CWRU) and Emory University (Emory).

The related works were published as first author in Nature (2016), Blood (2017), Journal of Molecular Liquids (2016), etc., and as corresponding author in journals such as Frontiers in Immunology (2017) and Experimental Hematology & Oncology (2016). Peer experts published special comments in Nature and other journals, stating that "expressing leukemia-associated genetic mutations in non-hematopoietic cells of the bone marrow is sufficient to induce leukemia in mice. Moreover, this discovery represents a major advancement in the treatment of frequently occurring fatal diseases."